Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects

被引:7
|
作者
Lang, CC [1 ]
Stein, CM [1 ]
He, HB [1 ]
Wood, AJJ [1 ]
机构
[1] VANDERBILT UNIV, SCH MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37232 USA
关键词
D O I
10.1016/S0009-9236(96)90007-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: One suggested mechanism for the reduction in mortality rates resulting from the use of angiotensin converting enzyme inhibitors in congestive heart failure is the inhibition of the angiotensin II-mediated norepinephrine release, Direct evidence for this mechanism is lacking in humans. Subjects and Methods: We examined the effects of captopril, 25 mg three times a day, or matched placebo for 7 days on sympathetic activity during a 10mEq/day sodium diet in seven healthy male subjects aged 30 +/- 3 (SEM) years, A tritiated norepinephrine radioisotope dilution technique was used to measure sympathetic activity, both at rest and during isometric handgrip exercise, Results: Captopril blunted the increase in mean arterial pressure during isometric handgrip exercise (placebo, from 81 +/- 4 to 112 +/- 2 mm Hg; captopril, from 75 +/- 3 to 101 +/- 2 mm Hg; p < 0.01), However, the increase in systemic norepinephrine spillover during isometric handgrip exercise was not blunted by captopril. Captopril had no effect on resting mean arterial pressure or systemic norepinephrine spillover, Conclusions:: Captopril did not attenuate baseline or static exercise-stimulated sympathetic activity in healthy subjects, These findings would indicate that angiotensin converting enzyme inhibition does not decrease sympathetic activity at rest or during the stimulus of isometric handgrip exercise.
引用
收藏
页码:668 / 674
页数:7
相关论文
共 50 条
  • [41] COUGH AND ANGIOTENSIN CONVERTING ENZYME-INHIBITION
    GILCHRIST, NL
    BRITISH MEDICAL JOURNAL, 1988, 297 (6643): : 293 - 293
  • [42] COUGH AND ANGIOTENSIN CONVERTING ENZYME-INHIBITION
    BROWN, RC
    TURTON, CWG
    BRITISH MEDICAL JOURNAL, 1988, 296 (6638): : 1741 - 1741
  • [43] INHIBITION OF ANGIOTENSIN CONVERTING ENZYME BY PHOSPHORAMIDATES AND POLYPHOSPHATES
    GALARDY, RE
    BIOCHEMISTRY, 1982, 21 (23) : 5777 - 5781
  • [44] Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
    Devin, Jessica K.
    Pretorius, Mias
    Nian, Hui
    Yu, Chang
    Billings, Frederic T.
    Brown, Nancy J.
    HYPERTENSION, 2014, 63 (05) : 951 - 957
  • [45] ANGIOTENSIN-CONVERTING ENZYME-INHIBITION, ANGIOTENSIN, AND COGNITION
    BARNES, JM
    BARNES, NM
    COSTALL, B
    COUGHLAN, J
    KELLY, ME
    NAYLOR, RJ
    TOMKINS, DM
    WILLIAMS, TJ
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 19 : S63 - S71
  • [46] Vasorelaxation to angiotensin I after angiotensin converting enzyme inhibition
    Baltatu, O
    Todiras, M
    Bader, M
    HYPERTENSION, 2000, 36 (04) : 695 - 695
  • [47] Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries
    Sivieri, Disney O., Jr.
    Bispo-da-Silva, Luiz B.
    Oliveira, Eduardo B.
    Resende, Angela C.
    Salgado, Maria Cristina O.
    HYPERTENSION, 2007, 50 (01) : 110 - 115
  • [48] EFFECT OF FOOD ON THE BIOAVAILABILITY OF PENTOPRIL, AN ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR, IN HEALTHY-SUBJECTS
    RAKHIT, A
    HURLEY, ME
    REDALIEU, E
    KOCHAK, G
    TIPNIS, V
    COLEMAN, J
    ROMMEL, A
    JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (06): : 424 - 428
  • [49] Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
    Manuel Haschke
    Manfred Schuster
    Marko Poglitsch
    Hans Loibner
    Marc Salzberg
    Marcel Bruggisser
    Joseph Penninger
    Stephan Krähenbühl
    Clinical Pharmacokinetics, 2013, 52 : 783 - 792
  • [50] Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
    Haschke, Manuel
    Schuster, Manfred
    Poglitsch, Marko
    Loibner, Hans
    Salzberg, Marc
    Bruggisser, Marcel
    Penninger, Joseph
    Kraehenbuehl, Stephan
    CLINICAL PHARMACOKINETICS, 2013, 52 (09) : 783 - 792